tbuckley/cabot-search huggingface dataset:
Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry
Authors: M.C.P. Kuppen, H.M. Westgeest, A.J.M. van den Eertwegh, J. Van Moorselaar, N. Mehra, J.L. Coenen, I. van Oort, A.C.M. van den Bergh, J. Lavalaye, K.K.H. Aben, D.M. Somford, R. de Wit, A.M. Bergman, C. Uyl-de Groot, W.R. Gerritsen
Journal: Annals of Oncology (2019)
Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer
Authors: K. Saleh, M. Carton, V.C. Dieras, P.-E. Heudel, E. Brain, N. Firmin, A. Mailliez, A. Patsouris, M.A. Mouret Reynier, A. Gonçalves, J.-M. Ferrero, T. Petit, C. Levy, L. Uwer, P.H. Cottu, L. Veron, E. Deluche, A. Savignoni, M. Robain, S. Delaloge
Journal: Annals of Oncology (2019)
Use of Leflunomide for Treatment of Cytomegalovirus Infection in Recipients of Allogeneic Stem Cell Transplant
Authors: Anant Gokarn, Anup Toshniwal, Amogh Pathak, Sankalp Arora, Avinash Bonda, Pankaj Dwivedi, Sachin Punatar, Vivek Bhat, Sanjay Biswas, Rohini Kelkar, Tapan Saikia, Sadhana Kannan, Navin Khattry
Journal: Blood (2017)
Population Genetics and Molecular Evolution of DNA Sequences in Transposable Elements. II. Accumulation of Variation and Evolution of a New Subfamily
Authors: Watal M Iwasaki, T E Kijima, Hideki Innan
Journal: Molecular Biology and Evolution (2019)

In order to understand how DNA sequences of transposable elements (TEs) evolve, extensive simulations were carried out. We first used our previous model, in which the copy number of TEs is mainly controlled by selection against ectopic recombination. It was found that along a simulation run, the shape of phylogeny changes quite much, from monophyletic trees to dimorphic trees with two clusters. Our results demonstrated that the change of the phase is usually slow from a monomorphic phase to a dimorphic phase, accompanied with a growth of an internal branch by accumulation of variation between two types. Then, the phase immediately changes back to a monomorphic phase when one group gets extinct. Under this condition, monomorphic and dimorphic phases arise repeatedly, and it is very difficult to maintain two or more different types of TEs for a long time. Then, how a new subfamily can evolve? To solve this, we developed a new model, in which ectopic recombination is restricted between two types under some condition, for example, accumulation of mutations between them. Under this model, because selection works on the copy number of each types separately, two types can be maintained for a long time. As expected, our simulations demonstrated that a new type arises and persists quite stably, and that it will be recognized as a new subfamily followed by further accumulation of mutations. It is indicated that how ectopic recombination is regulated in a genome is an important factor for the evolution of a new subfamily.
Gynecologic primitive neuroectodermal tumors are characterized by MIC-2 expression and the absence of common EWS-ETS translocations
Authors: Karen Hajra, R. Kevin Reynolds, Kathleen Cho
Journal: Cancer Research (2007)

2711  Objectives: Primitive neuroectodermal tumors (PNETs) uncommonly arise in gynecologic primary sites and represent a diagnostic and therapeutic challenge. Further understanding of the immunophenotype and genomic translocations of gynecologic PNETs may facilitate accurate tumor diagnosis.  Methods: Six gynecologic PNET cases were identified through our institution, four uterine, one cervical, and one arising in the round ligament. Immunohistochemical staining was done for MIC-2, vimentin, S-100, neuron-specific enolase, chromogranin A, synaptophysin, desmin, and PGP 9.5. For analysis of EWS-ETS translocations characteristic of PNETs, RNA was extracted from formalin-fixed, paraffin-embedded tumor specimens. cDNA synthesis and PCR amplification were performed with standard methods, using PCR primers detecting approximately 85% of EWS-FLI1 and EWS-ERG fusion transcripts.  Results: MIC-2 was expressed in all cases. Five cases had membranous MIC-2 staining and expressed neuron-specific enolase. One uterine case had punctate, cytoplasmic MIC-2 staining and failed to express neuron-specific enolase. All cases were negative for synaptophysin and chromogranin A. Variable staining was observed for the remaining proteins. For translocation analysis, RNA extraction was successful from five of six specimens, yet RT-PCR failed to demonstrate the presence of common EWS-FLI1 and EWS-ERG translocations.  Conclusions: The tumors diagnosed at our institution as gynecologic PNETs uniformly expressed MIC-2. However, the absence of commonly reported translocations in the tumors analyzed suggests that gynecologic PNETs may harbor novel EWS-ETS translocations. Alternatively, given the lack of genetic findings consistent with the diagnosis of PNET, perhaps a broader diagnostic spectrum should be entertained in evaluating the MIC-2-positive gynecologic small blue cell tumor.
Trends and Characteristics in Marijuana Use Among Public School Students — King County, Washington, 2004–2016
Authors: Myduc Ta, Lindsey Greto, Kaylin Bolt
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Use of marijuana at an early age can affect memory, school performance, attention, and learning; conclusions have been mixed regarding its impact on mental health conditions, including psychosis, depression, and anxiety (1-3). Medical marijuana has been legal in Washington since 1998, and in 2012, voters approved the retail sale of marijuana for recreational use to persons aged ≥21 years. The first retail stores opened for business in July 2014. As more states legalize marijuana use by adults aged ≥21 years, the effect of legalization on use by youths will be important to monitor. To guide planning of activities aimed at reducing marijuana use by youths and to inform ongoing policy development, Public Health-Seattle & King County assessed trends and characteristics of past 30-day marijuana use among King County, Washington, public school students in grades 6, 8, 10, and 12. This report used biennial data for 2004-2016 from the Washington State Healthy Youth Survey. Among grade 6 students there was a decreasing trend in self-reported past 30-day marijuana use from 2004 to 2016, while the percentage of grade 8 students who had used marijuana during the past 30 days did not change during that period. Among students in grades 10 and 12, self-reported past 30-day use of marijuana increased from 2004 to 2012, then declined from 2012 to 2016. In 2016, the percentage of students with past 30-day marijuana use in King County was 0.6% among grade 6, 4.1% among grade 8, 13.9% among grade 10, and 25.5% among grade 12 students. Among grade 10 students, 24.0% of past 30-day marijuana users also smoked cigarettes, compared with 1.3% of nonusers. From 2004 to 2016 the prevalence of perception of great risk of harm from regular marijuana use decreased across all grades. Continued surveillance using consistent measures is needed to monitor the impact of marijuana legalization and emerging public health issues, given variable legislation approaches among jurisdictions.
Precision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial
Authors: W. Boulfoul, C. Baldini, I. Borget, P. Martin Romano, L. Verlingue, L. Lacroix, E. Angevin, E. Rouleau, A. Varga, S. Postel Vinay, A. Gazzah, R. Bahleda, A. Marabelle, V. Ribrag, P. Vuagnat, S. Champiat, J.-M. Michot, A. Hollebecque, J.-C. Soria, C. Massard
Journal: Annals of Oncology (2019)
Folate receptor-positive circulating tumour cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Authors: X. Chen, F. Zhou, X. Li, C. Zhao, W. Li, F. Wu, J. Yu, G. Gao, J. Li, A. Li, S. Ren, C. Zhou
Journal: Annals of Oncology (2019)
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Authors: Daniel M. Ramos, Constantin d’Ydewalle, Vijayalakshmi Gabbeta, Amal Dakka, Stephanie K. Klein, Daniel A. Norris, John Matson, Shannon J. Taylor, Phillip G. Zaworski, Thomas W. Prior, Pamela J. Snyder, David Valdivia, Christine L. Hatem, Ian Waters, Nikhil Gupte, Kathryn J. Swoboda, Frank Rigo, C. Frank Bennett, Nikolai Naryshkin, Sergey Paushkin, Thomas O. Crawford, Charlotte J. Sumner
Journal: Journal of Clinical Investigation (2019)

BACKGROUNDSpinal muscular atrophy (SMA) is caused by deficient expression of survival motor neuron (SMN) protein. New SMN-enhancing therapeutics are associated with variable clinical benefits. Limited knowledge of baseline and drug-induced SMN levels in disease-relevant tissues hinders efforts to optimize these treatments.METHODSSMN mRNA and protein levels were quantified in human tissues isolated during expedited autopsies.RESULTSSMN protein expression varied broadly among prenatal control spinal cord samples, but was restricted at relatively low levels in controls and SMA patients after 3 months of life. A 2.3-fold perinatal decrease in median SMN protein levels was not paralleled by comparable changes in SMN mRNA. In tissues isolated from nusinersen-treated SMA patients, antisense oligonucleotide (ASO) concentration and full-length (exon 7 including) SMN2 (SMN2-FL) mRNA level increases were highest in lumbar and thoracic spinal cord. An increased number of cells showed SMN immunolabeling in spinal cord of treated patients, but was not associated with an increase in whole-tissue SMN protein levels.CONCLUSIONSA normally occurring perinatal decrease in whole-tissue SMN protein levels supports efforts to initiate SMN-inducing therapies as soon after birth as possible. Limited ASO distribution to rostral spinal and brain regions in some patients likely limits clinical response of motor units in these regions for those patients. These results have important implications for optimizing treatment of SMA patients and warrant further investigations to enhance bioavailability of intrathecally administered ASOs.FUNDINGSMA Foundation, SMART, NIH (R01-NS096770, R01-NS062869), Ionis Pharmaceuticals, and PTC Therapeutics. Biogen provided support for absolute real-time RT-PCR.
AB1167 Method comparison of aeskuslides anca for the diagnosis of anca-associated vasculitis
Authors: A. Lerner, T. Matthias, K. Prager, T. Barth, S. Reuter, J. Bär, S. Bush, M. Walle
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> AESKUSLIDES ANCA is an indirect immunofluorescence assay used to detect anti-neutrophil cytoplasmic autoantibodies (ANCA) in human serum. This <i>in vitro</i> diagnostic assay is used as an aid for the diagnosis of ANCA-associated vasculitis (AAV) in conjunction with other clinical and laboratory findings. <h3>Methods</h3> A method comparison of ethanol and formalin fixed granulocytes was carried out between AESKUSLIDES ANCA (AESKU. Diagnostics) and the NOVA Lite ANCA of INOVA. 507 clinical serum samples (comprising 135 serum samples from patients with AAV and 375 samples from patients with other diseases) were analysed by standard IFA protocols. Results were obtained by manual processing and reading. <h3>Results</h3> In this cohort, AESKUSLIDES ANCA Ethanol slides show higher sensitivities (48.5% vs. 36.4%) and specificities (69.3% vs. 55.2%) compared to INOVA. AESKUSLIDES ANCA Formalin slides show higher sensitivities (50.0% vs. 37.9%) and similar specificities (90.7% vs 91.5%) compared to INOVA. <h3>Conclusions</h3> AESKUSLIDES ANCA Ethanol showed higher diagnostic sensitivity (48.5%) and specificity (69.3%) compared to the predicate assay NOVA Lite provided by INOVA (36.4%, 55.2%). This is due to the fact, that AESKU assay detects more positives in the AAV cohort, and less positives in the other disease groups. AESKUSLIDES ANCA Formalin showed a diagnostic sensitivity (50.0%) compared to the predicate assay NOVA Lite provided by INOVA (37.9%). However, the diagnostic sensitivity was comparable between the two (90.7% vs 91.5%). <h3>Disclosure of Interest</h3> None declared
Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Authors: R. Dummer, D.E. Gyorki, J. Hyngstrom, A. Berger, R. Conry, L. Demidov, A. Sharma, S.A. Treichel, K. Gorski, A. Anderson, M. Faries, M.I. Ross
Journal: Annals of Oncology (2019)
Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)
Authors: D. Talbot, S.M. Fish, T. Jin Ong, E.D. Flick, D.M. Waterhouse
Journal: Annals of Oncology (2019)
DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy
Authors: A. Prelaj, C. Proto, G Lo Russo, D. Signorelli, R. Ferrara, G. Galli, A. De Toma, G. Randon, F. Pagani, B. Travisan, M. Ganzinelli, N. Zilembo, F.G.M. De Braud, M. Mensah, V. Torri, M.C. Garassino, G. Sozzi, M. Boeri
Journal: Annals of Oncology (2019)
Allergy to rabbits
Authors: J. A. Warner, J. L. LONGBOTTOM
Journal: Allergy (1991)

Crossed immunoelectrophoresis and crossed radio‐immunoelectrophoresis techniques have been employed for analysis of extracts of various rabbit source materials to identify rabbit allergens in addition to the already described Antigen R1 (AgR1). Urine and dander extracts were found to contain only low levels of AgR1 and its presence in urine was as a contaminant due to mode of collection – it was not present in urine collected directly from the bladder. Other allergens were only recognised by highly rabbit‐sensitive individuals, one in particular (Ag2) being present in several source materials. Serum albumin proved to be of minor allergenic importance and except for dander its presence was only in minimal amounts. As both AgR1 and Ag2 are significant components in extracts of fur and dust these extracts are therefore most recommended for use in investigations of individuals sensitive to rabbits.
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Authors: P. Schmid, J. Cortés, R. Dent, L. Pusztai, H.L. McArthur, S. Kuemmel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, P.A. Fasching, F. Cardoso, L. Jia, V. Karantza, J. Zhao, G. Aktan, J. O’Shaughnessy
Journal: Annals of Oncology (2019)
Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
Authors: E. Borazanci, A. Schram, I. Brana, M Vieito Villar, E. Garralda, A. Spreafico, M. Oliva, N. Lakhani, R. Wasserman, K. Hoffman, R. Hallett, J. Anido, P. Giblin, N. Pandya, A. Kelly, J. Seoane, D.D. Von Hoff, L.L. Siu, D.M. Hyman, J. Tabernero
Journal: Annals of Oncology (2019)
WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients
Authors: F.J. Ros Montana, P. Iranzo, A. Pedrola, A. Callejo, N. Pardo, R. Amat, C. Carbonell, A. Martinez, A. Navarro, S. Cedres, R. Dienstmann, H.G. Palmer, A. Vivancos, E. Felip
Journal: Annals of Oncology (2019)
Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance)
Authors: A. Fernandez-Martinez, M. Tanioka, C. Fan, J.S. Parker, K.A. Hoadley, I. Krop, A. Partridge, L. Carey, C.M. Perou
Journal: Annals of Oncology (2019)
Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Authors: A. Guzek, A.S. Berghoff, J. Jasinska, E. Garner-Spitzer, A. Wagner, H. Holzmann, M. Kundi, C.C. Zielinski, U. Wiedermann
Journal: Annals of Oncology (2019)
National small cell bladder cancer audit: Results from 26 UK institutions
Authors: C. Chau, Y. Rimmer, A. Law, D. Leaning, J.H. Lim, T. Young, S. Hafeez, D. Mitchell, J. McGrane, M. Beresford, N. Vasudev, V.-R. Sim, A. Koutalopoulou, S. Hilman, C. Manetta, S. Rajagopalan, A. Sharma, C. Eswar, D.R. Henderson, S. Crabb
Journal: Annals of Oncology (2019)
Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a multicenter phase II (REMORA) trial
Authors: S. Itoh, M. Satouchi, J. Sato, Y. Okuma, S. Niho, H. Mizugaki, H. Murakami, Y. Fujisaka, T. Kozuki, K. Nakamura, Y. Nagasaka, M. Kawasaki, T. Yamada, A. Kuchiba, N. Yamamoto
Journal: Annals of Oncology (2019)
Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
Authors: A. Marabelle, M.G. Fakih, J. Lopez, M. Shah, R. Shapira-Frommer, K. Nakagawa, H.C. Chung, H.L. Kindler, J.A. Lopez-Martin, W. Miller, A. Italiano, S. Kao, S.A. Piha-Paul, J.-P. Delord, R.R. McWilliams, D. Aurora-Garg, M. Chen, F. Jin, K. Norwood, Y.-J. Bang
Journal: Annals of Oncology (2019)
45 Gy versus 54 Gy of accelerated hyperfractionated thoracic radiotherapy for patients with limited-stage small-cell lung cancer.
Authors: Kanji Matsuura, Tsuyoshi Katsuta, Masayuki Kagemoto
Journal: Journal of Clinical Oncology (2016)

e20104 Background: The optimal dose of accelerated hyperfractionated radiotherapy (AHF-RT) for limited-stage small-cell lung cancer (L-SCLC) remains unknown. The purpose of this study was to evaluate the efficacy and safety of AHF-TRT with 54 Gy. Methods: Between 2006 and 2012, 19 patients, diagnosed with L-SCLC and treated with chemotherapy and thoracic radiation therapy (TRT), were enrolled in this study. The chemotherapy regimens were PE (cisplatin and etoposide) or CE (carboplatin and etoposide) regimens. Nine patients treated between 2006 and 2010 were irradiated with 45 Gy in 30 fractions for 3 weeks with AHF. Ten patients treated between 2011 and 2012 were irradiated with 54 Gy in 36 fractions for 3.6 weeks with AHF. AHF-RT was given in two phases: patients initially received 36 Gy to gross tumor plus uninvolved mediastinal nodes, followed by a boost to gross tumor of 9 or 18 Gy. All patients were treated with three-dimensional conformal radiation therapy with multiple fields to reduce irradiated volume of surrounding organ to a minimum as far as possible, such as esophagus. Results: The median survival time (MST) of 45 Gy group was 24 months, while MST of 54 Gy group was 41 months. A comparison between the 45 Gy and 54 Gy groups at three years showed that the overall survival rate was 33.3% vs 60.0%, (p = 0.3036); the progression-free survival (PFS) rate was 0% vs 40.0% (p = 0.0191); the in-field progression-free survival rate was 11.1% vs. 50.0% (p = 0.0917) and the distant metastasis-free survival (DMFS) rate was 60.0% vs. 0% (p = 0.0293). No Grade 3+ non-hematological adverse effects, such as acute esophagitis, pneumonitis or lung fibrosis were encountered. Conclusions: TRT with AHF of 54 Gy with concurrent PE or CE regimens significantly improved PFS and DMFS controls without increasing severe toxicity, compared with 45 Gy. Although more patients with longer follow-up periods are needed to evaluate the usefulness and safety of dose escalation of 9 Gy, these outcomes suggest that the dose escalation to 54 Gy on AHF-RT for L-SCLC could be a promising modality to improve the treatment results with low incidence of severe toxicity.
Changes in clinico-pathological characteristics of vulvar cancer in Japan: Increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Authors: S. Nishio, K. Matsuo, T. Shibata, S. Yamaguchi, H. Kanao, K. Takehara, N. Kado, A. Tozawa, H. Tokunaga, T. Matsunaga, H. Kato, K. Horie, A. Kikuchi, T. Enomoto, M. Mikami
Journal: Annals of Oncology (2019)
HLA-G 3’UTR polymorphism are associated with different patterns of tissue expression and severity of liver injury in chronic hepatitis B infection
Authors: S. Ferreira, S.G.F. Chachá, F.C. Dias, R.D.C. Santana, J.C. de Oliveira Crispim, M.O. Brunaldi, C. Mendes-Junior, L.N.Z. Ramalho, E. Donadi, A.D.L.C. Martinelli
Journal: Journal of Hepatology (2018)
Analysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial
Authors: M. Robson, Z. Lai, S. Dearden, J.C. Barrett, E.A. Harrington, K. Timms, J. Lanchbury, W. Wu, A. Allen, C. Goessl, E. Senkus, S. Domchek, D. Hodgson
Journal: Annals of Oncology (2019)
SP0164 Comorbidity of RA and Other Rheumatic Diseases
Authors: K. Hyrich
Journal: Annals of the Rheumatic Diseases (2015)

This WIN session will focus on recent advances regarding the occurrence, impact and management of comorbidities in the rheumatic diseases, including cardiovascular, pulmonary and psychiatric/psychological disease. The session will focus primarily on rheumatoid arthritis but important publications regarding other inflammatory arthritides and related diseases in adults will also be reviewed. In particular, publication highlights over the past 12 months will be presented. <h3>Disclosure of Interest</h3> K. Hyrich Consultant for: Pfizer, Abbvie
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK
Authors: S.-E. Al-Batran, C. Pauligk, R.D. Hofheinz, S. Lorenzen, A. Wicki, A.R. Siebenhuener, M. Schenk, P.C. Thuss-Patience, A. Kretzschmar, C. Bolling, E. Eigendorff, S. Angermeier, D. Pink, M. Geissler, E. Goekkurt, H. Schmalenberg, L. Waberer, J.J. Talbot, T.O. Goetze, N. Homann
Journal: Annals of Oncology (2019)
A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)
Authors: P. Hammel, J-B. Bachet, F. Portales, L. Mineur, J-P. Metges, C. de la Fouchardiere, C. Louvet, F. El Hajbi, R. Faroux, R. Guimbaud, D. Tougeron, J. Volet, T. Lecomte, C. Tournigand, C. Rebischung, W. Berlier, A. Gupta, J. Cros, T. André, I. El-Hariry
Journal: Annals of Oncology (2017)
Identification of the founder BRCA1 mutation c.4117G&gt;T (p.Glu1373*) recurring in the Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Authors: D Di Giacomo, M. Calicchia, S. Candria, G. Bruera, S. Ferella, E. Lucci Cordisco, M. Tosi, M. Genuardi, E. Ricevuto
Journal: Annals of Oncology (2019)
Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Authors: F. Barlesi, M. Özgüroğlu, J.F. Vansteenkiste, D. Spigel, J C-H Yang, M. Bajars, M. Ruisi, J. Manitz, K. Park
Journal: Annals of Oncology (2019)
Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study
Authors: J.E. Alés-Martínez, S. Morales, M. Fernández Abad, P. Sánchez-Rovira, F.J. Salvador Bofill, A. Lahuerta, J.A. García-Sáenz, I. Garau Llinas, T. Díaz Redondo, N. Ferrer, V. Carañana, R. López, S.E. Alonso Soler, B. Bermejo, J. de la Haba, P. Zamora, J. Balmana, E. López-Miranda, J. Cortés, A. Llombart Cussac
Journal: Annals of Oncology (2019)
A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Authors: T. Yokoyama, K. Ninomiya, I. Oze, T. Hata, A. Tanaka, A. Bessho, S. Hosokawa, S. Kuyama, K. Kudo, T. Kozuki, D. Harada, M. Yasugi, T. Murakami, M. Nakanishi, N. Takigawa, K. Katsui, Y. Maeda, K. Hotta, K. Kiura
Journal: Annals of Oncology (2019)